Supplementary Data

Identification, structural modification, and dichotomous effects on human immunodeficiency virus type 1 (HIV-1) replication of ingenane esters from *Euphorbia kansui*

Qingbo Liu ^{a,b}, Wei Li ^{a,*}, Li Huang ^c, Yoshihisa Asada ^a, Susan L. Morris-Natschke ^d, Chin-Ho Chen ^{c,*}, Kuo-Hsiung Lee ^{d,e,*},Kazuo Koike ^{a,*}

^a Faculty of Pharmaceutical Sciences, Toho University, Miyama 2-2-1, Funabashi, Chiba 274-8510, Japan
^b Key Laboratory of Structure-Based Drug Design and Discovery of Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, China.

^c Surgical Science, Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, United States

^d Natural Products Research Laboratories, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, United States

^e Chinese Medicine Research and Development Center, China Medical University and Hospital, Taichung 40402, Taiwan

Correspondence:

E-mail addresses: liwei@phar.toho-u.ac.jp (W. Li). chc@duke.edu (C.-H. Chen). khlee@unc.edu (K.-H. Lee). koike@phar.toho-u.ac.jp (K. Koike).

Table of Contents

Anti-HIV activities of <i>E. kansui</i> MeOH extract and fractions (E1-4)	S2
Selective deacylation of ingenane esters 1 and 5	S2
LC-MS analysis	S4
Spectra data of 10	S6
Preparation details of 19-21	S6
HRMS, IR and NMR spectra	S10

Anti-HIV activities of E. kansui MeOH extract and fractions (E1-4)

Extract	anti-HIV	cytotoxicity
	EC_{50} (µg/ml)	CC ₅₀ (µg/ml)
MeOH extract	0.15	>10
EtOAc fraction	0.11	>10
H ₂ O fraction	>10	>10
E1	1.3	>10
E2	>10	>10
E3	0.028	9.4
E4	0.86	>10

	TableS1. Anti-HIV	activities of E.	kansui MeOH	extract and fractions
--	-------------------	------------------	-------------	-----------------------

Selective deacylation of ingenane esters 1 and 5.



A solution of **1** (4 mg, 9 µmol) or **5** (4 mg, 6 µmol) and potassium carbonate (3 mg, 15 µmol) in 3 mL of anhydrous methanol was stirred at room temperature for 3 h, diluted with diethyl ether, washed with water. After removal of solvent *in vacuo*, the residue was purified by RP-HPLC (YMC Pack Pro C₁₈, MeCN-H₂O, 50:50 and 90:10, 5 mL/min) to give **9** (2.6 mg, 82%, t_R = 22.0 min) and **11** (2.3 mg, 70%, t_R = 25.5 min).

20-Deoxyingenol (**9**): colorless oil; [α]_D²⁵-13.5 (*c* 0.2, MeOH); UV (MeCN) λmax (log ε): 205 (4.34) nm; IR (KBr) max: 2923, 1707, 1449, 1379, 1460, 1261, 1168, 1100, 1098, 801 cm⁻¹; ¹H NMR (pyridine-*d*₅, 500 MHz) δ 6.23 (1H, q, J = 1.2 Hz, H-1), 5.02 (1H, d, J = 5.8 Hz, H-3), 3.87 (1H, d, J = 10.9 Hz, H-5), 5.90 (1H, dq, J = 4.8, 1.4 Hz, H-7), 4.60 (1H, ddq, J = 11.2, 4.8, 2.0 Hz, H-8), 2.80 (1H, qdd, J = 7.2, 4.6, 3.0 Hz, H-11), 2.63 (1H, ddd, J = 15.4, 8.9, 3.0 Hz, H₂-12a), 1.75 (1H, ddd, J = 15.4, 6.3, 4.6 Hz, H₂-12b), 0.75 (1H, ddd, J = 8.9, 8.6, 6.3 Hz, H-13), 1.17 (dd, J = 12.1, 8.6 Hz, H-14), 1.06 (3H, s, H₃-16), 1.24 (3H, s, H₃-17), 1.14 (3H, d, J = 7.2 Hz, H₃-18), 1.89 (3H, d, J = 1.2 Hz, H₃-19), 1.96 (3H, brs, H₃-20); ¹³C NMR (pyridine- d_5 , 125 MHz) δ 129.5 (C-1), 140.3 (C-2), 80.6 (C-3), 85.9 (C-4), 77.0 (C-5), 140.4 (C-6), 123.1 (C-7), 44.4 (C-8), 207.4 (C-9), 73.3 (C-10), 39.9 (C-11), 31.4 (C-12), 23.7 (C-13), 24.3 (C-14), 24.1 (C-15), 28.7 (C-16), 15.8 (C-17), 17.5 (C-18), 15.7 (C-19), 22.8 (C-20); positive-ion HRESIMS *m*/*z* 355.1878 [M+Na]⁺, (calcd for C₂₀H₂₈O₄Na, 355.1885).

13-Oxyingenol-13-dodecanoate (**11**): colorless oil; $[α]_p^{25}$ -41.4 (*c* 0.2, CHCl₃); UV (MeCN) λmax (log ε): 203 (4.31); IR (KBr) max: 2926, 1727, 1605, 1458, 1379, 1260, 1021, 800 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 5.90 (1H, brq, *J* = 1.6 Hz, H-1), 4.40 (1H, s, H-3), 3.82 (1H, brs, H-5), 5.90 (1H, dd, *J* = 4.9, 1.4 Hz, H-7), 4.06 (1H, brdd, *J* = 11.7, 4.0 Hz, H-8), 2.42 (1H, m, H-11), 2.63 (1H, dd, *J* = 16.6, 4.2 Hz, CH₂-12a), 2.18 (1H, overlap, CH₂-12b), 1.28 (1H, overlap, H-14), 1.05 (3H, s, H₃-16), 1.20 (H, s, CH₃-17), 0.95 (3H, d, *J* = 7.2 Hz, H₃-18), 1.84 (3H, d, *J* = 1.5 Hz, H₃-19), 4.16 (1H, d, *J* = 12.6 Hz, H₂-20a), 4.11 (1H, d, *J* = 12.6 Hz, H₂-20b), 2.18 (2H, t, *J* = 6.9 Hz, H₂-2'), 1.55 (2H, overlap, H₂-3'), 1.27-1.21 (16H, m, H₂-4'-H₂-11'), 0.86 (3H, t, *J* = 6.9 Hz, H₃-12') ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 129.3 (C-1), 139.3 (C-2), 80.4 (C-3), 84.1 (C-4), 75.3 (C-5), 140.8 (C-6), 126.1 (C-7), 43.3 (C-8), 206.2 (C-9), 72.6 (C-10), 38.7 (C-11), 35.1 (C-12), 68.9 (C-13), 28.3 (C-14), 30.3 (C-15), 22.5 (C-16), 16.7 (C-17), 18.4 (C-18), 15.3 (C-19), 66.8 (C-20), 174.0 (C-1'), 34.4 (C-2'), 24.8 (C-3'), 29.7-29.2 (C-4'-C-11'), 14.1 (C-12'); positive-ion HRESIMS *m*/z 569.3475 [M+Na]⁺, (calcd for C₃₂H₅₀O₇Na, 569.3454).

ESI-MS fragmentation behavior of isolated ingenane esters (1–5) and monitoring deacylation by LC-MS analysis

The reference solutions of 1-5 were prepared by dissolving them in LC-MS grade acetonitrile, and were made up at a concentration of 0.1 mg/mL. The samples (E3-fraction and E3-fraction after deacylation of *E. kansui* MeOH extract) used for LC-MS analysis were prepared by dissolving in MeOH at a concentration of 2.5 mg/mL. All the samples were filtered on 0.45 µm filter.

LC-MS analysis was performed on a Shimadzu LCMS-8040 Triple Quadrupole LC/MS/MS Mass Spectrometer. Nitrogen was used as the dry, nebulizer and auxiliary heated gas, and ultrapure helium was used as the collision gas. The ESI parameters were set as follows: interface voltage (4.5 kV in the positive-ion mode and -3.5 kV in the negative-ion mode); collision voltage, 15 V; dry gas, 15 L/min; dry temperature, 350 °C. Both the positive and negative ionization modes were checked, data reported in the range of m/z 100-800 Da.

HPLC was performed using a Shimadzu 8040 system (Shimadzu, Kyoto, Japan), which was equipped with a binary solvent delivery system and an auto-sampler. Separation was performed on a YMC-Triart C₁₈ column (150 mm × 20 mm) maintained at 35°C, and the flow rate was 0.2 mL/min. The mobile phase was composed of A (0.1% formic acid in aqueous solution) and B (acetonitrile) with a gradient elution: 0-30 min, 50%-100% B, and the column was equilibrated for 20 min under the initial conditions. A volume of 2 μ L was injected for LC-MS analysis. ESI-MS fragmentation behavior of **1-5** in positive ion mode was shown in Figure S1.



Figure S1. Proposed main ESI-MS fragmentation behavior of 1-5 in positive ion mode.

Physical and spectroscopic data of ingenol (10).



Ingenol (10): colorless oil; $[\alpha]_{D}^{25}$ -44.6 (*c* 0.4, CHCl₃); UV (MeCN) λmax (log ε): 203 (4.31) nm; IR (KBr) max: 2935, 1710, 1454, 1379, 1460, 1150, 1017, 756 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 6.03 (1H, brd, *J* = 4.3 Hz, H-1), 4.37 (1H, s, H-3), 3.79 (1H, brs, H-5), 5.90 (1H, dd, *J* = 3.1, 1.7 Hz, H-7), 4.10 (1H, overlap, H-8), 2.32 (1H, m, H-11), 2.26 (1H, ddd, *J* = 15.5, 8.9, 2.8 Hz, H₂-12a), 1.74 (1H, ddd, *J* = 15.5, 6.3, 5.1 Hz, H₂-12b), 0.68 (1H, ddd, *J* = 8.9, 8.9, 6.3 Hz, H-13), 0.92 (1H, dd, *J* = 12.0, 8.9 Hz, H-14), 1.04 (3H, s, H₃-16), 1.10 (3H, s, H₃-17), 0.95 (3H, d, *J* = 6.8 Hz, H₃-18), 1.83 (3H, d, *J* = 1.5 Hz, H₃-19), 4.15 (1H, d, *J* = 12.6 Hz, H₂-20a), 4.10 (1H, d, *J* = 12.6 Hz, H₂-20b) ppm; ¹³C NMR (CDCl₃, 125 MHz) δ 129.8 (C-1), 138.9 (C-2), 80.5 (C-3), 84.3 (C-4), 75.3 (C-5), 140.4 (C-6), 127.4 (C-7), 44.1 (C-8), 207.2 (C-9), 72.6 (C-10), 39.7 (C-11), 30.9 (C-12), 23.2 (C-13), 23.0 (C-14), 23.9 (C-15), 28.5 (C-16), 15.5 (C-17), 17.3 (C-18), 15.4 (C-19), 66.9 (C-20); positive-ion HRESIMS *m/z* 371.1823 [M+Na]⁺, (calcd for C₂₀H₂₈O₅Na, 371.1834).

Preparation of ingenol-5,20-acetonide (19).



To a stirred solution of **10** (11 mg, 32 μ mol) in acetone (6 mL) was added *p*-TsOH·H₂O (0.5 mg, 2.6 μ mol) at room temperature for 2 h. After removal of solvent *in vacuo*, the residue passed through a Sep-

Pak C18 cartridge (Waters) using MeCN-H₂O (10:90 and 100:0, each 10.0 ml) as solvents. Then, CH₃CN-H₂O (100:0) eluate was purified by RP-HPLC (YMC Pack Pro C₁₈, MeCN-H₂O, 60:40, 5 mL/min) to give **19** (8.3 mg, 66.8%, $t_R = 21.0$ min).

Ingenol-5,20-acetonide (19): colorless oil; $[\alpha]_{p}^{25}$ -26.1 (*c* 0.3, CHCl₃); UV (MeCN) λmax (log ε): 204 (4.14) nm; IR (KBr) max: 2924, 1724, 1469, 1379, 1261, 1222, 1157, 1077 cm⁻¹; ¹H NMR (CDCl₃, 500 MHz) δ 5.90 (1H, q, *J* = 1.7 Hz, H-1), 4.23 (1H, s, H-3), 3.91 (1H, brs, H-5), 5.78 (1H, dq, *J* = 4.0, 1.7 Hz, H-7), 4.10 (1H, overlap, H-8), 2.47 (1H, m, H-11), 2.24 (1H, ddd, *J* = 15.8, 8.3, 3.1 Hz, H₂-12a), 1.76 (1H, ddd, *J* = 15.8, 6.3, 5.5 Hz, H₂-12b), 0.69 (1H, ddd, *J* = 8.3, 8.3, 6.3 Hz, H-13), 0.91 (1H, dd, *J* = 11.8, 8.3 Hz, H-14), 1.03 (3H, s, H₃-16), 1.10 (3H, s, H₃-17), 0.95 (3H, d, *J* = 7.2 Hz, H₃-18), 1.83 (3H, d, *J* = 1.7 Hz, H₃-19), 4.15 (1H, d, *J* = 12.6 Hz, H₂-20a), 4.10 (1H, d, *J* = 12.6 Hz, H₂-20b), 1.39 (3H, s, H₃-2'), 1.33 (3H, s, H₃-3'); ¹³C NMR (CDCl₃, 125 MHz) δ 129.5 (C-1), 136.1 (C-2), 80.0 (C-3), 83.3 (C-4), 73.8 (C-5), 139.6 (C-6), 122.3 (C-7), 44.0 (C-8), 207.6 (C-9), 72.9 (C-10), 38.3 (C-11), 31.2 (C-12), 23.6 (C-13), 23.0 (C-14), 23.8 (C-15), 28.6 (C-16), 15.6 (C-17), 17.8 (C-18), 15.6 (C-19), 64.2 (C-20), 100.6 (C-1'), 26.6 (C-2'), 21.1 (C-3'); positive-ion HRESIMS *m/z* 411.2147 [M+Na]⁺, (calcd for C₂₃H₃₂O₅Na, 411.2159).

Preparation of 3-angeloylingenol-5,20-acetonide (20).



To a stirred solution of diol **19** (2.7 mg, 7 µmol) in MeCN (2.0 ml) were added Cs₂CO₃ (9 mg, 27.6 µmol) and angelic anhydride (5 µL, 28 µmol) at room temperature for 4 h. After removal of solvent *in vacuo*, the residue passed through a Sep-Pak C18 cartridge (Waters) using MeCN-H₂O (10:90 and 100:0, each 10 mL) as solvents to obtain **20** (3 mg, 95.7%, $t_R = 21.0$ min).

3-Angeloylingenol-5,20-acetonide (**20**): colorless oil; ¹H NMR (CDCl₃, 500 MHz) δ 6.03 (1H, brq, J = 1.5 Hz, H-1), 5.64 (1H, s, H-3), 4.00 (1H, brs, H-5), 5.78 (1H, dq, J = 4.0, 2.0 Hz, H-7), 4.15 (1H, m, H-8), 2.59 (1H, m, H-11), 2.25 (1H, ddd, J = 15.7, 8.9, 2.8 Hz, CH₂-12a), 1.73 (1H, ddd, J = 15.7, 6.3, 5.5 Hz, CH₂-12b), 0.67 (1H, ddd, J = 8.9, 8.3, 6.5 Hz, H-13), 0.89 (1H, dd, J = 12.0, 8.3 Hz, H-14), 1.05 (3H, s, H₃-16), 1.15 (3H, s, H₃-17), 0.95 (3H, d, J = 7.1 Hz, H₃-18), 1.76 (3H, d, J = 1.7 Hz, H₃-19), 4.19 (1H, d, J = 12.6 Hz, H₂-20a), 4.13 (1H, d, J = 12.6 Hz, H₂-20b), 1.44 (3H, s, CH₃-2'), 1.40 (3H, s, CH₃-3'), 6.06 (1H, qq, J = 7.1, 1.5 Hz, H-3"), 2.00 (1H, dq, J = 7.2, 1.5 Hz, H-4"), 1.91 (3H, qui, J = 1.5 Hz, CH₃-5"); ¹³C NMR (CDCl₃, 125 MHz) δ 132.5 (C-1), 136.8 (C-2), 81.5 (C-3), 84.1 (C-4), 74.0 (C-5), 136.2 (C-6), 122.2 (C-7), 43.6 (C-8), 208.0 (C-9), 72.3 (C-10), 37.5 (C-11), 30.9 (C-12), 23.2 (C-13), 22.8 (C-14), 23.9 (C-15), 28.3 (C-16), 15.4 (C-17), 17.2 (C-18), 15.5 (C-19), 64.2 (C-20), 100.5 (C-1'), 26.5 (C-2'), 21.1 (C-3'), 168.5 (C-1"), 128.1 (C-2"), 138.2 (C-3"), 15.5 (C-4"), 20.6 (C-5").

Preparation of 3-(2-naphthoyl)ingenol-5,20-acetonide (21).



To a stirred solution of diol **19** (2.7 mg, 7 µmol) in dehydrated DCM (3 mL) were added DMAP (3 mg, 25 µmol) and 2-naphthoic acid (5 mg, 29 µmol), and chilled to 0 °C. A solution of EDCI (4 mg, 20 µmol) dissolved in dehydrated DCM (0.5 mL) was added dropwise, and the reaction mixture was stirred at room temperature for 4 h under protection of argon. After removal of solvent *in vacuo*, the residue was purified by RP-HPLC (YMC Pack Pro C₁₈, MeCN-H₂O, 80:20, 5.0 mL/min) to give **21** (2.6 mg, 68.6%, $t_R = 28.5$ min).

3-(2-naphthoyl)ingenol-5,20-acetonide (21): colorless oil; ¹H NMR (CDCl₃, 500 MHz) δ 6.14 (1H,

brq, J = 1.5 Hz, H-1), 5.84 (1H, s, H-3), 4.08 (1H, brs, H-5), 5.78 (1H, dq, J = 4.0, 1.7 Hz, H-7), 4.18 (1H, ddq, J = 11.7, 4.0, 2.3 Hz, H-8), 2.74 (1H, m, H-11), 2.26 (1H, ddd, J = 15.8, 8.9, 3.2 Hz, H₂-12a), 1.73 (1H, ddd, J = 15.8, 8.3, 6.3 Hz, H₂-12b), 0.67 (1H, ddd, J = 8.9, 8.6, 6.0 Hz, H-13), 0.91 (1H, dd, J = 11.8, 8.3 Hz, H-14), 1.03 (3H, s, H₃-16), 1.05 (3H, s, H₃-17), 1.08 (3H, d, J = 7.1 Hz, H₃-18), 1.80 (3H, d, J = 1.2 Hz, H₃-19), 4.23 (1H, d, J = 12.6 Hz, H₂-20a), 4.15 (1H, d, J = 12.6 Hz, H₂-20b), 1.50 (3H, s, H₃-2'), 1.47 (3H, s, H₃-3'), 8.03 (1H, dd, J = 8.6, 1.5 Hz, H-3"), 7.89 (1H, d, J = 8.6 Hz, H-4"), 7.87 (1H, brd, J = 8.0 Hz, H-5"), 7.58 (1H, ddd, J = 8.0, 6.9, 1.2 Hz, H-6"), 7.53 (1H, ddd, J = 8.0, 6.9, 1.2 Hz, H-7"), 7.95 (1H, brd, J = 8.0 Hz, H-8"), 8.58 (1H, brs, H-9"); ¹³C NMR (CDCl₃, 125 MHz) δ 132.7 (C-1), 136.5 (C-2), 82.7 (C-3), 84.3 (C-4), 74.1 (C-5), 135.8 (C-6), 124.2 (C-7), 43.4 (C-8), 207.5 (C-9), 72.4 (C-10), 37.9 (C-11), 31.3 (C-12), 23.6 (C-13), 23.0 (C-14), 24.0 (C-15), 28.5 (C-16), 15.5 (C-17), 17.6 (C-18), 15.6 (C-19), 64.4 (C-20), 100.5 (C-1'), 26.8 (C-2'), 20.9 (C-3'), 167.6 (C-1"), 127.5 (C-2"), 125.3 (C-3"), 128.3 (C-4"), 127.7 (C-5"), 128.4 (C-6"), 126.7 (C-7"), 129.4 (C-8"), 131.3 (C-9"), 132.5 (C-10"), 135.6 (C-11").



The IR spectrum of compound 9



The ¹H spectrum of compound **9**



The ¹³C spectrum of compound **9**



The DEPT spectrum of compound 9



The DQF_COSY spectrum of compound 9



The HSQC spectrum of compound 9



The HMBC spectrum of compound 9



The IR spectrum of compound 10



The ¹H spectrum of compound **10**



The ¹³C spectrum of compound **10**



The DEPT spectrum of compound ${\bf 10}$



The DQF_COSY spectrum of compound 10



The HSQC spectrum of compound 10



The HMBC spectrum of compound 10



The IR spectrum of compound 11



The ¹H spectrum of compound **11**



The ¹³ C spectrum of compound **11**

The HSQC spectrum of compound 11

The HMBC spectrum of compound 11

The NOESY spectrum of compound 11

The IR spectrum of compound 12a

The ¹H spectrum of compound**12a**

The ${}^{13}C$ spectrum of compound **12a**

The DEPT spectrum of compound 12a

The DQF_COSY spectrum of compound 12a

The HSQC spectrum of compound 12a

The HMBC spectrum of compound 12a

The NOESY spectrum of compound 12a

The IR spectrum of compound 12b

The ¹H spectrum of compound **12b**

The ¹³C spectrum of compound **12b**

The DEPT spectrum of compound 12b

The DQF_COSY spectrum of compound 12b

The HSQC spectrum of compound 12b

The NOESY spectrum of compound 12b

The IR spectrum of compound 13a

The ¹H spectrum of compound **13a**

The ¹³C spectrum of compound **13a**

The DEPT spectrum of compound 13a

The DQF_COSY spectrum of compound 13a

The HMBC spectrum of compound 13a

The NOESY spectrum of compound 13a

The HRESIMS spectrum of compound 13b

The ¹H spectrum of compound **13b**


The ¹³C spectrum of compound **13b**



The DQF_COSY spectrum of compound 13b



The HSQC spectrum of compound 13b















The IR spectrum of compound 14a



The ¹H spectrum of compound **14a**



The ¹³C spectrum of compound **14a**







The DQF_COSY spectrum of compound 14a



The HSQC spectrum of compound 14a



The HMBC spectrum of compound 14a



The NOESY spectrum of compound 14a



The IR spectrum of compound 14b



The ¹H spectrum of compound **14b**



The ¹³C spectrum of compound **14b**



The DEPT spectrum of compound 14b



The DQF_COSY spectrum of compound 14b



The HSQC spectrum of compound 14b



The HMBC spectrum of compound 14b



The NOESY spectrum of compound 14b



The HRFABMS spectrum of compound 15a



The IR spectrum of compound 15a



The ¹H spectrum of compound **15a**



The ${}^{13}C$ spectrum of compound **15a**



The DEPT of compound 15a



The DQF_COSY of compound 15a



The HSQC of compound 15a



The HMBC of compound 15a



The NOESY of compound 15a







The IR spectrum of compound KS-3



The ¹H spectrum of compound **15b**



The ¹³C spectrum of compound **15b**



The DEPT spectrum of compound 15b



The DQF_COSY spectrum of compound 15b



The HSQC spectrum of compound 15b



The HMBC spectrum of compound 15b



The NOESY spectrum of compound 15b







The IR spectrum of compound 16



The ¹H spectrum of compound **16**



The ¹³C spectrum of compound **16**



The DEPT spectrum of compound16



The DQF_COSY spectrum of compound 16



The HSQC spectrum of compound 16



The HMBC spectrum of compound 16



The NOESY spectrum of compound 16



The IR spectrum of compound 17



The ¹H spectrum of compound **17**



The ¹³C spectrum of compound **17**



The DEPT spectrum of compound 17



The DQF_COSY spectrum of compound 17



The HSQC spectrum of compound 17



The HMBC spectrum of compound 17



The NOESY spectrum of compound 17



The HRESIMS spectrum of compound 18



The IR spectrum of compound 18



The ¹H spectrum of compound **18**



The ¹³C spectrum of compound **18**



The DQF_COSY spectrum of compound 18



The HSQC spectrum of compound 18



The HMBC spectrum of compound 18



The NOESY spectrum of compound 18



The HRESIMS spectrum of compound 19







The ¹H spectrum of compound **19**



The ¹³C spectrum of compound **19**



The DQF_COSY spectrum of compound 19


The HSQC spectrum of compound 19



The HMBC spectrum of compound 19



The NOESY spectrum of compound 19



The ¹H spectrum of compound **20**



The ¹³C spectrum of compound **20**



The DEPT spectrum of compound 20



The DQF_COSY spectrum of compound 20



The HSQC spectrum of compound 20



The HMBC spectrum of compound 20



The ¹H spectrum of compound **21**



The ¹³C spectrum of compound **21**



The DEPT spectrum of compound 21



The DQF_COSY spectrum of compound 21



The HSQC spectrum of compound 21



The HMBC spectrum of compound 21



The HRESIMS spectrum of compound 22







The ¹H spectrum of compound **22**



The ¹³C spectrum of compound 22









The HSQC spectrum of compound 22



The HMBC spectrum of compound 22



The NOESY spectrum of compound 22



The IR spectrum of compound 23



The ¹H spectrum of compound **23**



The ¹³C spectrum of compound 23



The DQF_COSY spectrum of compound 23



The HSQC spectrum of compound 23



The HMBC spectrum of compound 23



The NOESY spectrum of compound 23